No righteous man exists without honoring books. Manuscript book of the Russian North of the 15th – 20th centuries (exhibition materials)

The article represents the review of manuscript books of the 15th – 20th centuries introduced at the exhibition “No righteous man exists without honoring books. Manuscript book of the Russian North of the 15th– 20th centuries”. All exhibits are stored at the State Museum Association “Artistic Culture of the Russian North”. The museum’s collection includes many impressive monuments of traditional Russian literature, as well as manuscripts of the Old Believer environment. For several years, attribution of manuscript monuments was carried out. The result of scientific research was a catalog. The fascinating books in terms of content and artistic performance are exhibited at the museum. The exhibition stands show many miniatures, screensavers, and other elements of book design. Each visitor of the exhibition will find something interesting for himself: the creation of manuscript monuments, the genre variety of the Northern book, the decoration of texts, the development of the decorative design of manuscripts, the variety of singing books. All exhibited manuscripts are presented for the first time. For this purpose, special exhibition equipment, shop windows, and a lighting system under the museum standards were used

Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype

© 2020 Medical Education. All rights reserved. Biological therapy of bronchial asthma (BA) is a modern method of treating severe forms of the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations are registered in the world for the treatment of severe bronchial asthma (SBA) of the T2 endotype (T2-SBA) - antibodies, binding to immunoglobulin (Ig) E (anti-IgE - omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 - mepolizumab, resizumab) and its receptor (anti-IL-5Rα - benralizumab), as well as antibodies, that selectively bind to the IL-4 and -13 receptor (anti-IL-4 /13Rα - dupilumab). The article presents data on the effectiveness of these drugs in relation to the key characteristics of SBA, formulates clinical and laboratory criteria, the study of which in real practice can potentially predict the likelihood of a clinical response to a particular type of biological therapy. An algorithm is proposed for choosing a targeted therapy strategy for patients with SBA, clinically associated with allergies, for patients with severe non-allergic eosinophilic BA and for patients with eosinophilic BA of a combined phenotype